Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.

National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892-7434, USA, Tel.: +1 301 496 0975.
Personalized Medicine (Impact Factor: 1.13). 01/2010; 7(1):33-47. DOI: 10.2217/pme.09.49
Source: PubMed

ABSTRACT Physicians need improved tools for selecting treatments for individual patients. Many diagnostic entities hat were traditionally viewed as individual diseases are heterogeneous in their molecular pathogenesis and treatment responsiveness. This results in the treatment of many patients with ineffective drugs, incursion of substantial medical costs for the treatment of patients who do not benefit and the conducting of large clinical trials to identify small, average treatment benefits for heterogeneous groups of patients. In oncology, new genomic technologies provide powerful tools for the selection of patients who require systemic treatment and are most (or least) likely to benefit from a molecularly targeted therapeutic. In the large amount of literature on biomarkers, there is considerable uncertainty and confusion regarding the specifics involved in the development and evaluation of prognostic and predictive biomarker diagnostics. There is a lack of appreciation that the development of drugs with companion diagnostics increases the complexity of clinical development. Adapting to the fundamental importance of tumor heterogeneity and achieving the benefits of personalized oncology for patients and healthcare costs will require paradigm changes for clinical and statistical investigators in academia, industry and regulatory agencies. In this review, I attempt to address some of these issues and provide guidance on the design of clinical trials for evaluating the clinical utility and robustness of prognostic and predictive biomarkers.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastoma (GBM) is the most common and most aggressive primary malignant tumor of the central nervous system. Recently, researchers concluded that the "one-size-fits-all" approach for treatment of GBM is no longer valid and research should be directed toward more personalized and patient-tailored treatment protocols. Identification of the molecular and genomic pathways underlying GBM is essential for achieving this personalized and targeted therapeutic approach. Imaging genomics represents a new era as a noninvasive surrogate for genomic and molecular profile identification. This article discusses the basics of imaging genomics of GBM, its role in treatment decision-making, and its future potential in noninvasive genomic identification. Copyright © 2015 Elsevier Inc. All rights reserved.
    Neuroimaging Clinics of North America 02/2015; 25(1):141-153. DOI:10.1016/j.nic.2014.09.010 · 1.29 Impact Factor
  • Edited by Van Montfort, K., Oud, J., & Ghidey, W. (Eds.)., 01/2014; Springer., ISBN: ISBN 978-3-642-55344-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The process for using statistical inference to establish personalized treatment strategies requires specific techniques for data-analysis that optimize the combination of competing therapies with candidate genetic features and characteristics of the patient and disease. A wide variety of methods have been developed. However, heretofore the usefulness of these recent advances has not been fully recognized by the oncology community, and the scope of their applications has not been summarized. In this article, we provide an overview of statistical methods for establishing optimal treatment rules for personalized medicine and discuss specific examples in various medical contexts with oncology as an emphasis. We also point the reader to statistical software for implementation of the methods when available.
    BioMed Research International 01/2015; · 2.71 Impact Factor

Full-text (2 Sources)

Available from
Sep 17, 2014